Pre-made Abrilumab benchmark antibody ( Whole mAb, anti-α4β7/Integrin alpha 4 beta 7 therapeutic antibody, Anti-LPAM‑1 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-005
Pre-Made Abrilumab biosimilar, Whole mAb, Anti-α4β7/Integrin alpha 4 beta 7 Antibody: Anti-LPAM‑1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abrilumab (INN; development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.This drug was developed by MedImmune.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Abrilumab biosimilar, Whole mAb, Anti-α4β7/Integrin alpha 4 beta 7 Antibody: Anti-LPAM‑1 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Crohn's disease;Ulcerative colitis|